RESISTANCE TO TARGETED THERAPIES IN MELANOMA: NEW INSIGHTS
Several molecular mechanisms are involved in melanoma genesis and progression. Molecular targets for effective therapeutic intervention have been identified within the RAS-RAF-MEK-ERK and, to a less extent, PI3K-AKT pathways. The development of inhibitors of key effectors (mainly BRAF mutant, MEK,...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2013-12-01
|
| Series: | European Medical Journal Dermatology |
| Subjects: | |
| Online Access: | https://emj.emg-health.com/wp-content/uploads/sites/2/2013/12/Resistance-to-Targeted-Therapies-in-Melanoma-New-Insights.pdf |
| Summary: | Several molecular mechanisms are involved in melanoma genesis and progression. Molecular targets for
effective therapeutic intervention have been identified within the RAS-RAF-MEK-ERK and, to a less extent,
PI3K-AKT pathways. The development of inhibitors of key effectors (mainly BRAF mutant, MEK, and
KIT) into such pathways has significantly improved the treatment of patients with advanced melanoma.
However, emerging data indicate that a large variety of acquired and intrinsic mechanisms may drive
resistance to the main targeted inhibitors. All the evidence suggests that in melanoma, as probably in
all types of cancer, it is unlikely that targeting a single component in pathogenetic signalling pathways
could yield significant antitumour responses. Therefore, knowledge of the multiple altered signalling
events involved in response and resistance to targeted treatments will allow for the development of more
effective combination therapies, which may represent the next challenge for the management of patients
with such a disease |
|---|---|
| ISSN: | 2054-6211 2054-6211 |